Paul G. Allen Frontiers Group [to 9 Nov 2019]
Press Release
The Paul G. Allen Frontiers Group Names New Allen Distinguished Investigators
November 6, 2019
Five new awardees will embark on stem cell and tissue research with the potential to impact human health”
Samantha Morris, Ph.D.
Washington University in St. Louis
Joshua Rabinowitz, Ph.D.
Princeton University
Clive Svendsen, Ph.D.
Savas Tay, Ph.D.
University of Chicago
James Wells, Ph.D.
Cincinnati Children’s Hospital Medical Center


BMGF – Gates Foundation [to 9 Nov 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 9 Nov 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 9 Nov 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
11.06.2019  |
CARB-X funds Techulon to support the development of innovative nano therapeutics capable of killing drug-resistant bacteria by precisely targeting essential genes
Techulon project is the 50th project funded by CARB-X since it was launched in 2016
(BOSTON, MA)  – CARB-X is awarding Techulon Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, VA, USA, up to $785,000 in non-dilutive funding to develop a new class of antimicrobial that would kill drug-resistant bacteria by targeting specific genes critical to the bacteria’s survival. The CARB-X award supports preclinical hit-to-lead development of Techulon’s drug candidates targeting Acinetobacter baumannii and Pseudomonas aeruginosa, two superbugs that have been identified by the World Health Organization (WHO) as ‘priority pathogens’ posing the greatest threat to global health and by the US Centers for Disease Control and Prevention (CDC) as ‘serious threats’ to human health.
The Techulon project is the 50th innovative antibacterial early development project funded by CARB-X, established in July 2016. To date, CARB-X has invested more than $150 million in non-dilutive funding to accelerate the development of antibiotics, vaccines, diagnostics and other life-saving products to address drug-resistant bacteria, with additional funds committed if projects achieve certain milestones. The CARB-X portfolio has 31 active projects in five countries…


CEPI – Coalition for Epidemic Preparedness Innovations [to 9 Nov 2019]
No new digest content identified.


Clinton Health Access Initiative, Inc. (CHAI) [to 9 Nov 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 9 Nov 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 9 Nov 2019]
No new digest content identified.


European Medicines Agency [to 9 Nov 2019]
News & Press Releases
No new digest content identified.


European Vaccine Initiative [to 9 Nov 2019]
No new digest content identified.


FDA [to 9 Nov 2019]
Press Announcements
November 8, 2019 – FDA approves first therapy to treat patients with rare blood disorder
Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions…

November 6, 2019 – Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices
… The Cures Act included a new requirement that the FDA make our best practices for drug safety surveillance publicly available on the web. Following the passage of the Cures Act we posted a statement announcing the risk-based principles we use for postmarket safety surveillance. Today, we’re announcing the availability of our draft document, “Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff,” which expands upon those principles. This draft best practice document outlines our approach for timely postmarket analyses of drugs and biologics, and includes a high-level overview of tools, methods, and signal detection and evaluation activities, using varied data sources, for drug safety surveillance to provide a broader context and a general overview of our overarching effort and commitment in this area….


Fondation Merieux [to 9 Nov 2019]
News, Events
December 3 – 4, 2019 – Geneva (Switzerland)
Mérieux Foundation co-organized event
6th GTFCC Working Group on Oral Cholera Vaccine

20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)


Gavi [to 9 Nov 2019]
Latest news
05 November 2019
Democratic Republic of Congo launches major push against measles, cholera, and rotavirus
Measles follow-up immunisation campaign, emergency oral cholera vaccine campaign, and rotavirus vaccine introduction to protect millions against combination of epidemics.


GHIT Fund [to 9 Nov 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 9 Nov 2019]
News & Stories
Funding Model
Updated Documents and Technical Guidance for Applicants
08 November 2019
Updated resources for applicants are now available on the Global Fund website in preparation for the 2020-2022 funding period.

These documents have been updated:
:: Funding requests forms and instructions on the Funding Request Applications page
:: Programmatic gap tables on the Funding Request Applications page
:: Funding Landscape Table download in English | Español | Français
:: Modular Framework Handbook download in English | Español | Français

Applicants can familiarize themselves with the following core technical investment documents:
:: HIV Information Note download in English | Español | Français
:: Tuberculosis Information Note download in English | Español | Français
:: Malaria Information Note download in English | Español | Français
:: Building Resilient and Sustainable Systems for Health through Global Fund Investments Information Note download in English | Español | Français


Hilleman Laboratories [to 9 Nov 2019]
No new digest content identified.


Human Vaccines Project [to 9 Nov 2019]
Press Releases
No new digest content identified.


IAVI [to 9 Nov 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



No new digest content identified.


IFRC [to 9 Nov 2019]
Selected Press Releases, Announcements
Mozambique: Thousands at risk of disease and malnutrition as rainy season begins
Beira/Geneva, 8 November 2019—More than half a year since cyclones Idai and Kenneth hit Mozambique, thousands of people are at risk of disease outbreaks and worsening food insecurity during the coming rainy season.  Food insecurity is expected to affec …
8 November 2019

Asia Pacific
Philippines: Thousands in need of humanitarian assistance after Mindanao earthquakes
More than 180,000 people are affected with many families requiring humanitarian assistance after a series of powerful earthquakes, struck Cotabato province in Mindanao, Philippines.
5 November 2019


IVAC [to 9 Nov 2019]
10 Years of Progress in Global Immunization Programs Celebration
The International Vaccine Access Center (IVAC) will be celebrating its 10th anniversary on December 9, 2019 with an event at the Johns Hopkins Bloomberg School of Public Health featuring Executive Director Dr. Bill Moss, Senior Advisor Mathu Santosham, and a keynote address by Dr. Orin Levine, Director of Global Delivery Programs at the Bill and Melinda Gates Foundation and the original founder of IVAC. Comments by Dr. Kate O’Brien, IVAC’s immediate past Executive Director and current Director of Immunization, Vaccines and
Biologicals at the World Health Organization, will open the event.


IVI [to 9 Nov 2019]
Selected IVI News & Announcements
IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety
Institute expected to increase contributions to vaccine development activities worldwide
November 1, 2019


JEE Alliance [to 9 Nov 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 9 Nov 2019]
Latest [Selected Announcements]
More than 5,000 patients treated during MSF respons…
Project Update 8 Nov 2019

DRC Ebola outbreaks
Crisis update – November 2019
Crisis Update 5 Nov 2019

Four questions on the malaria outbreak in western Sudan
Interview 4 Nov 2019


National Vaccine Program Office – U.S. HHS [to 9 Nov 2019]
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)


NIH [to 9 Nov 2019]
Selected News Releases
Study vaccine protects monkeys against four types of hemorrhagic fever viruses
November 8, 2019 — The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.


PATH [to 9 Nov 2019]
Selected Announcements
November 7, 2019 by PATH
Blood pressure check with your manicure?
Communities for Healthy Hearts in Vietnam uses local volunteers and businesses to help people with hypertension discover their condition and take steps to manage it


Sabin Vaccine Institute [to 9 Nov 2019]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 9 Nov 2019]
Selected Press Releases/Reports/Statements
7 November 2019
Confronting the link between HIV and gender-based violence in Jamaica

5 November 2019
Worldwide, more than half of new HIV infections now among key populations and their sexual partners
… Key populations make up a small proportion of the general population, but they are at extremely high risk of acquiring HIV infection. Available data suggest that the risk of HIV acquisition among gay men and other men who have sex with men was 22 times higher in 2018 than it was among all adult men. Similarly, the risk of acquiring HIV for people who inject drugs was 22 times higher than for people who do not inject drugs, 21 times higher for sex workers than adults aged 15–49 years and 12 times higher for transgender women than adults aged 15–49 years….


UNICEF [to 9 Nov 2019]
Selected Statements, Press Releases, Reports
Press release
60,000 young refugees and migrants who arrived in Italy alone need ongoing support as they transition to adulthood – UN Agencies
Key challenges include discrimination, difficulty finding work, administrative bottlenecks and lack of legal information

Press release
200,000 children affected as heavy flooding in Somalia brings increased risk of malnutrition and disease outbreak
UNICEF and partners working to meet urgent needs of most vulnerable children


Vaccination Acceptance Research Network (VARN) [to 9 Nov 2019]
No new digest content identified.


Vaccine Confidence Project [to 9 Nov 2019]
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 9 Nov 2019]
No new digest content identified.


Wellcome Trust [to 9 Nov 2019]
News | 8 November 2019
We are carbon off-setting our travel

Twitter | 7 November 2019
A new science for epidemics must include these 7 disciplines (opens in a new tab)

Opinion | 5 November 2019
It’s time to rethink the way we talk about one of the most urgent threats to our health
by Jeremy Farrar
Tackling big health challenges is dependent on science and innovation, but also on the public understanding and engaging with them.

Opinion | 4 November 2019
7 things manifesto writers should know about science
by Martin Smith


The Wistar Institute [to 9 Nov 2019]
Press Release Nov. 8, 2019
Synthetic DNA Technology Applied as a Novel Strategy for Delivery of Anti-HIV Antibodies
Synthetic DNA-encoded monoclonal antibodies (DMAbs) allow for in vivo production of broadly neutralizing antibodies in preclinical studies.


World Organisation for Animal Health (OIE) [to 9 Nov 2019]
‘United Against Rabies’ collaboration celebrates one year of progress towards zero human rabies deaths by 2030
Since the launch of ‘Zero by 30’ in 2018, the United Against Rabies collaboration has made progress to empower, engage and enable countries to reach the rabies elimination goal by 2030. Released today on World Rabies Day, the first annual progress report describes the incremental, collaborative impact of the four partners[1] in promoting the One Health approach[2] and achieving the three objectives of the Global Strategic Plan.





ARM [Alliance for Regenerative Medicine] [to 9 Nov 2019]
November 5, 2019
The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics
Highlighted findings from the Q3 2019 data report include:
:: Globally, companies active in gene and cell therapies and other regenerative medicines raised nearly $2.6 billion in the third quarter of 2019, bringing the year-to-date total financings to more than $7.4 billion. The report also includes financial data broken out by technology type and financing type.
:: There were 1,052 clinical trials underway worldwide at the close of the third quarter of 2019, with more than 60% of those in oncology and 5% in musculoskeletal disorders and central nervous system disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.


BIO [to 9 Nov 2019]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network [to 9 Nov 2019]
No new digest content identified.


IFPMA [to 9 Nov 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 9 Nov 2019]
Selected Press Releases, Statements
No new digest content identified.